Intelligence · Clinical Development
Pipeline search results
Programs matching “gemcitabine” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 50 pipeline programs matching "gemcitabine" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Gemcitabine
LEXICON PHARMACEUTICALS, INC.
Locally Advanced Unresectable Pancreatic Adenocarcinoma
1 trial -
Gemcitabine
BRIGHT MINDS BIOSCIENCES INC.
Treatment Refusal
1 trial -
Gemcitabine
ACTUATE THERAPEUTICS, INC.
Sarcoma
1 trial -
Gemcitabine
Acrivon Therapeutics
Head and Neck Squamous Cell Carcinoma
1 trial -
Gemcitabine
Compass Therapeutics
Metastatic Biliary Tract Cancer
1 trial -
Gemcitabine , Docetaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sarcoma
1 trial -
Gemcitabine 1000 mg
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase II, Open-label, Parallel 2-arm, Multi-center
1 trial -
Gemcitabine Oxaliplatin 5FU and Leucovorin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pancreatic Cancer
1 trial -
Gemcitabine plus Cisplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Biliary Tract Cancer
1 trial -
Gemcitabine+5FU+Leucovorin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Biliary Tract Disease
1 trial -
Gemcitabine+simvastatin
Samsung Bioepis NL B.V.
Pancreatic Cancer
1 trial -
Gemcitabine/Cisplatin
BRIGHT MINDS BIOSCIENCES INC.
Upper Tract Urothelial Carcinoma
1 trial -
Injection of IAH0968+Gemcitabine+Cisplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HER2 Gene Mutation
1 trial -
Lenalidomide and Gemcitabine (Dose level 11)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral T-cell Lymphomas (PTCL)
1 trial -
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel
RELMADA THERAPEUTICS, INC.
Non Muscle Invasive Bladder Cancer
1 trial -
SYSUCC-CMY-2022-0416
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma
1 trial -
Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine
Sun Yat-sen University
Locally Advanced Pancreatic Cancer
1 trial -
chemotherapy: TS-1, Leucovorin and Gemcitabine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pancreatic Adenocarcinoma
1 trial -
gemcitabine
Yung NA
Muscle Invasive Bladder Urothelial Carcinoma
1 trial -
gemcitabine and cisplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Squamous Cell Carcinoma
1 trial -
gemcitabine and oxaliplatin.
The First People's Hospital of Lianyungang
Gallbladder Carcinoma
1 trial -
Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
RIGEL PHARMACEUTICALS INC
Pancreatic Ductal Adenocarcinoma (PDAC)
1 trial -
OMP-54F28, Nab-Paclitaxel and Gemcitabine
Mereo BioPharma Group plc
Pancreatic Cancer
1 trial -
Gemcitabine
HALOZYME THERAPEUTICS, INC.
Pancreatic Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.